Publications

5808 Results

The addition of gemtuzumab ozogamicin (GO) to induction chemotherapy reduces relapse and improves survival in patients without adverse risk karyotype: results of an individual patient meta-analysis of the five randomised trials

Authors
R Hills;S Petersdorf;E Estey;M Othus;F Appelbaum;S Castaigne;H Dombret;S Chevert;J Delaunay;N Ifrah;J-Y Chan;C Recher;AK Burnett
Journal / Conference
Blood 122:356, 2013; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), oral;
Year
2013
Research Committee(s)
Leukemia
PMID
n/a
PMC
n/a
Study Number(s)
S0106

The role of body mass index in survival outcome for lymphoma patients: an Eastern Cooperative Oncology Group Experience

Authors
F Hong;TM Habermann;LI Gordon;H Hochster;R Gascoyne;RI Fisher;N Bartlett;P Stiff;B Cheson;M Crump;S Horning;B Kahl
Journal / Conference
Blood 122:3060; American Society of Hematology annual meeting (Dec 7-10, 2013), poster;
Year
2013
Research Committee(s)
Lymphoma
Study Number(s)
E2496, E4494

Alteration of cytogenetic risk stratification in new diagnosis of leukemia by FISH testing - the SWOG experience

Authors
M Fang;S McDonough;M Othus;L Zhuo;D Roulston;H Erba;F Appelbaum
Journal / Conference
Blood 122:1383; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster;
Year
2013
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0112, S0301, S0325, S0333, S0432, S0521, S0530, S0535, S0605, S0703

Impact of cytarabine dose in the induction regimen on the outcome of patients with newly diagnosed acute myeloid leukemia with or without NPM1 and/or FLT3 mutations: A SWOG and MD Anderson Cancer Center Report

Authors
M Othus;F Ravandi;S Faderl;D Stirewalt;S Pierce;G Borthakur;J Godwin;J Anderson;S Petersdorf;J Cortes;F Ostronoff;E Pogosova-Agadijanyan;F Appelbaum;H Kantarjian;E Estey
Journal / Conference
Blood 122:2686; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster;
Year
2013
Research Committee(s)
Leukemia
Study Number(s)
S0106, SWOG-9031, SWOG-9333, SWOG-9500

NUP98/NSD1 translocation further risk-stratifies patients with FLT3/ITD in acute myeloid leukemia: A report from Children’s Oncology Group and SWOG

Authors
F Ostronoff;M Othus;RB Gerbing;MR Loken;S Raimondi;B Hirsch;BJ Lange;S Petersdorf;J Radich;F Appelbaum;AS Gamis;TA Alonzo;S Meshinchi
Journal / Conference
Blood 122:488; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), oral;
Year
2013
Research Committee(s)
Leukemia
Study Number(s)
S0106

Prognostic significance of NPM1 mutations in the absence of FLT3-ITD in older patients with AML: a SWOG report

Authors
F Ostronoff;M Othus;S Meshinchi;J Godwin;K Kopecky;A List;V Oehler;S Petersdorf;E Pogosolva-Agadjanyan;J Radich;CL Willman;F Appelbaum;D Stirewalt
Journal / Conference
Blood 122:1315; American Society of Hematology annual meeting (Dec 7-10, New Orleans, LA), poster;
Year
2013
Research Committee(s)
Leukemia
Study Number(s)
S0106, SWOG-9031, SWOG-9333, SWOG-9500

Selenium and prostate cancer prevention: insights from the selenium and vitamin E cancer prevention trial (SELECT)

Authors
HL Nicastro;BK Dunn
Journal / Conference
Nutrients 5(4):1122-1148
Year
2013
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID23552052
PMC
PMC3705339
Study Number(s)
S0000

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

Authors
K Flaherty;S Lee;F Zhao;L Schuchter;L Flaherty;R Kefford;M Atkins;P Leming;J Kirkwood
Journal / Conference
Journal of Clinical Oncology 31(3):373-379
Year
2013
Research Committee(s)
Melanoma
PMID
PMID23248256
PMC
PMC4878104
Study Number(s)
CTSU/E2603

International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease

Authors
E Terpos;G Morgan;M Dimopoulos;M Drake;S Lentzsch;N Raje;O Sezer
Journal / Conference
Journal of Clinical Oncology 31(18):2347-2357
Year
2013
Research Committee(s)
Myeloma
PMID
PMID23690408
PMC
PMC Journal - In process

Impact of c-myc protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (Alliance) N9831

Authors
AC Dueck;MM Reinholz;XJ Geiger;K Tenner;K Ballman;RB Jenkins;D Riehle;B Chen;AE McCullough;N Davidson;S Martino;GW Sledge;PA Kaufman;LA Kutteh;J Gralow;LN Harris;JN Ingle;WL Lingle;EA Perez
Journal / Conference
Clinical Cancer Research 19(20):5798-5807;
Year
2013
Research Committee(s)
Breast
PMID
PMID23965903
PMC
PMC3805021
Study Number(s)
N9831